{
    "title": "Glaxo breathes easier as lung drug may not face US competition until 2016",
    "url": "https://www.dailymail.co.uk/money/article-1327031/Glaxo-breathes-easier-lung-drug-face-US-competition-2016.html",
    "date": "2010-11-05",
    "keywords": [
        "advair",
        "drug",
        "approval",
        "glaxo",
        "market",
        "teva",
        "cent",
        "revenue",
        "competition",
        "strategy",
        "threat",
        "copy",
        "news",
        "product",
        "drugmaker",
        "relovair",
        "mail",
        "reporter",
        "gmt",
        "view",
        "lease",
        "life",
        "cutprice",
        "update",
        "firm",
        "glaxos",
        "maker",
        "today",
        "competitor",
        "higher",
        "afternoon",
        "advance",
        "sector",
        "share",
        "price",
        "glaxosmithkline",
        "barrage",
        "america",
        "company",
        "erosion",
        "fund",
        "manager",
        "analyst",
        "tevas",
        "decision",
        "novartis",
        "unit",
        "sandoz",
        "march",
        "development",
        "version",
        "vectura",
        "group",
        "plc",
        "europe",
        "form",
        "launch",
        "target",
        "vindication",
        "executive",
        "protection",
        "buffer",
        "lack",
        "transition",
        "treatment",
        "asthma",
        "disease",
        "copd",
        "theravance",
        "inc",
        "glimpse",
        "successor",
        "nextgeneration",
        "combination",
        "respiratory",
        "medicine",
        "finalstage",
        "phase",
        "testing"
    ],
    "category": [
        "money"
    ]
}